Research programme: adenosine A2A receptor agonists - Rocket Pharmaceuticals
Alternative Names: PJ-1165Latest Information Update: 09 Jan 2018
At a glance
- Originator Inotek Pharmaceuticals
- Class
- Mechanism of Action Adenosine A2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Atopic dermatitis; Inflammation; Rheumatoid arthritis
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 08 Aug 2007 Discontinued - Preclinical for Asthma in USA (Aerosol)
- 08 Aug 2007 Discontinued - Preclinical for Atopic dermatitis in USA (Topical)